Formulary coverage lookup tool

See formulary status in your area

Formulary status of CREON on selected plans in:

ZIP code (required)

Select a filter

Commercial

Medicare

State Medicaid

Health Exchange

Managed Medicaid

Please enter a valid zip code.

Plan name
Plan type
CREON coverage

Indications and Important Safety Information

Indications¹

CREON^® (pancrelipase) Delayed-Release Capsules is a pancrelipase which is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.

Important Safety Information

Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement in the treatment of cystic fibrosis patients. Exercise caution when doses of CREON exceed 2,500 lipase units/kg of body weight per meal (or greater than 10,000 lipase units/kg of body weight per day).
To avoid irritation of oral mucosa, care should be taken to ensure that CREON is not crushed, chewed, or retained in the mouth. CREON should always be taken with food.
Porcine-derived pancreatic enzyme products contain purines. Caution should be exercised when prescribing CREON to patients with gout, renal impairment, or hyperuricemia.
There is theoretical risk of viral transmission with all pancreatic enzyme products including CREON.
Exercise caution when administering pancrelipase to a patient with a known allergy to proteins of porcine origin.
Adverse reactions that occurred in at least 2 cystic fibrosis patients (greater than or equal to 4%) receiving CREON were vomiting, dizziness, and cough.
Adverse reactions that occurred in at least 1 chronic pancreatitis or pancreatectomy patient (greater than or equal to 4%) receiving CREON were hyperglycemia, hypoglycemia, abdominal pain, abnormal feces, flatulence, frequent bowel movements, and nasopharyngitis.
CREON is not interchangeable with any other pancrelipase product.

Please see Full Prescribing Information.

US-CREO-220154

Reference: 1. CREON [package insert]. North Chicago, IL: AbbVie Inc.

Indications and Important Safety Information

Indications¹

Important Safety Information

Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement in the treatment of cystic fibrosis patients. Exercise caution when doses of CREON exceed 2,500 lipase units/kg of body weight per meal (or greater than 10,000 lipase units/kg of body weight per day).
To avoid irritation of oral mucosa, care should be taken to ensure that CREON...

Indications and Important Safety Information

Indications¹

Important Safety Information

Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement in the treatment of cystic

Indications and Important Safety Information

Indications¹

Important Safety Information

Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement in the treatment of cystic fibrosis patients. Exercise caution when doses of CREON exceed 2,500 lipase units/kg of body weight per meal (or greater than 10,000 lipase units/kg of body weight per day).
To avoid irritation of oral mucosa, care should be taken to ensure that CREON...

Indications and Important Safety Information

Indications¹

Important Safety Information

Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement in the treatment of cystic

Indications and Important Safety Information

Indications¹

Important Safety Information

Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement in the treatment of cystic fibrosis patients. Exercise caution when doses of CREON exceed 2,500 lipase units/kg of body weight per meal (or greater than 10,000 lipase units/kg of body weight per day).
To avoid irritation of oral mucosa, care should be taken to ensure that CREON is not crushed, chewed, or retained in the mouth. CREON should always be taken with food.
Porcine-derived pancreatic enzyme products contain purines. Caution should be exercised when prescribing CREON to patients with gout, renal impairment, or hyperuricemia.
There is theoretical risk of viral transmission with all pancreatic enzyme products including CREON.
Exercise caution when administering pancrelipase to a patient with a known allergy to proteins of porcine origin.
Adverse reactions that occurred in at least 2 cystic fibrosis patients (greater than or equal to 4%) receiving CREON were vomiting, dizziness, and cough.
Adverse reactions that occurred in at least 1 chronic pancreatitis or pancreatectomy patient (greater than or equal to 4%) receiving CREON were hyperglycemia, hypoglycemia, abdominal pain, abnormal feces, flatulence, frequent bowel movements, and nasopharyngitis.
CREON is not interchangeable with any other pancrelipase product.

Please see Full Prescribing Information.

US-CREO-220154

Formulary coverage lookup tool

See formulary status in your area

Indications and Important Safety Information

Indications1

Important Safety Information

Indications and Important Safety Information

Indications1

Important Safety Information

Indications and Important Safety Information

Indications1

Important Safety Information

Indications and Important Safety Information

Indications1

Important Safety Information

Indications and Important Safety Information

Indications1

Important Safety Information

Indications and Important Safety Information

Indications1

Important Safety Information

Indications¹

Indications¹

Indications¹

Indications¹

Indications¹

Indications¹